

Literatur:

1. Mach F et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J*. 2025; <https://doi.org/10.1093/eurheartj/ehaf190>
2. Mach F et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). *Eur Heart J*. 2020;41:111-88
3. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. *Eur Heart J*. 2021;42:2439-54
4. Dzaye O et al. Coronary artery calcium scores indicating secondary prevention level risk: Findings from the CAC consortium and FOURIER trial. *Atherosclerosis*. 2022;347:70-6
5. Budoff MJ et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). *Eur Heart J*. 2018;39:2401-8
6. Peng AW et al. Very High Coronary Artery Calcium (≥ 1000) and Association With Cardiovascular Disease Events, Non-Cardiovascular Disease Outcomes, and Mortality. *Circulation*. 2021;143:1571-83
7. Kraaijenhof JM et al. Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study. *Eur Heart J*. 2025; <https://doi.org/10.1093/eurheartj/ehaf209>
8. Katsi V et al. The Role of Non-HDL Cholesterol and Apolipoprotein B in Cardiovascular Disease: A Comprehensive Review. *J Cardiovasc Dev Dis*. 2025;12:256
9. Ference BA et al. Mendelian Randomization Study of ACLY and Cardiovascular Disease. *N Engl J Med*. 2019;380:1033-42
10. Silverman MG et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. *JAMA*. 2016;316:1289-97
11. Leosdottir M et al. Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWE-DEHEART Registry. *J Am Coll Cardiol*. 2025;85:1550-64
12. Cannon CP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. *N Engl J Med*. 2015;372:2387-97
13. Schwartz GG et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. *N Engl J Med*. 2018;379:2097-107
14. Sabatine MS et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *N Engl J Med*. 2017;376:1713-22
15. Makhmudova U et al. Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction ("Jena auf Ziel"). *Clin Res Cardiol*. 2023;112:1212-9
16. Ballantyne CM et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. *Eur J Prev Cardiol*. 2020;27:593-603
17. Ray KK et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. *N Engl J Med*. 2019;380:1022-32
18. Nissen SE et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. *N Engl J Med*. 2023;388:1353-64
19. Raal FJ et al. Evinacumab for Homozygous Familial Hypercholesterolemia. *N Engl J Med*. 2020;383:711-20
20. Bhatt DL et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. *N Engl J Med*. 2019;380:11-22
21. Witztum JL et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial. *J Clin Lipidol*. 2023;17:342-55
22. Tsimikas S et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. *N Engl J Med*. 2020;382:244-55
23. O'Donoghue ML et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. *N Engl J Med*. 2022;387:1855-63
24. Nissen SE et al. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. *JAMA*. 2022;327:1679-87
25. Nissen SE et al. Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial. *JAMA*. 2023;330:2075-83
26. Nissen SE et al. Zelasiran—A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial. *JAMA*. 2024;332:1992-2002
27. Nicholls SJ et al. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial. *JAMA*. 2023;330:1042-53
28. Nicholls SJ et al. Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial. *JAMA*. 2025;333:222-31
29. Grinspoon SK et al. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection. *N Engl J Med*. 2023;389:687-99
30. Neilan TG et al. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial. *JAMA*. 2023;330:528-36
31. Ray KK et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. *Lancet Reg Health Eur*. 2023; [https://www.thelancet.com/journals/lanep/article/PIIS2666-7762\(23\)00043-1/fulltext](https://www.thelancet.com/journals/lanep/article/PIIS2666-7762(23)00043-1/fulltext); abgerufen am 15.01.2026
32. Weingärtner O et al. LipidSnapshot - Treatment gaps in hypercholesterolemia in patients with atherosclerotic cardiovascular disease documented by office-based cardiologists and general practitioners in Germany. *Clin Res Cardiol*. 2025; <https://doi.org/10.1007/s00392-025-02751-z>